-

$undefined

N/A

(N/A)

Legend Biotech Corporation NASDAQ:LEGN Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. The team of over 800 employees across the United States, China and Europe, along with its differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture cutting edge cell therapies for patients in need.

Location: 2101 Cottontail Lane, New Jersey, 08873, United States | Website: www.legendbiotech.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

13.7B

Cash

1.212B

Avg Qtr Burn

-39.4M

Short % of Float

7.80%

Insider Ownership

1.32%

Institutional Own.

55.58%

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CARVYKTI (cilta-cel) (ciltacabtagene autoleucel) Details Blood cancer, Cancer, Multiple myeloma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CARVYKTI (cilta-cel) Details Blood cancer, Cancer, Multiple myeloma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (DVRd) Details Multiple myeloma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LB2102 Details Cancer, Small cell lung cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LB1901 (antiCD4) Details Cancer, T-cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.